Placeholder Banner

BIO Comments to FDA on their Workshop to Enhance Clinical Study Diversity

January 29, 2024

Following the FDA Workshop to Enhance Clinical Study Diversity on November 29-30, 2023, BIO submits specific comments per the request for information (FDA-2023-N-2462).

Download Full Comments Below
bio_comment_letter_-_fda-2023-n-2462_-_clinical_study_diversity_workshop.pdf
Discover More
The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments regarding the request and comments on the Advanced Manufacturing Technologies Designation Program Draft Guidance.
The Biotechnology Innovation Organization thanks the Food and Drug Administration for the opportunity to submit comments regarding the request for information and comments on the Food and Drug Administration's Draft Report and Plan on Best Practices…
In response to the request for information and comments, BIO submitted general comments and recommended edits (FDA-2017-D-6530)